Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations
Date: 2024-02-27 Authors: David S. Hong, Federico Cappuzzo, Byoung Chul Cho, Afshin Dowlati, Maen Hussein, Dong-Wan Kim, Ivor Percent, James G. Christensen, JosĂ©e Morin, Diane Potvin, Demiana Faltaos, Vanessa Tassell, Hirak Der-Torossian, Richard Chao Category:Other Objectives: Dysregulated signaling by mesenchymal epithelial transition factor (MET) and heightened AXL activation are implicated in the pathogenesis of non-small […]
Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study
Date: 2023-08-02 Authors: Melissa L. Johnson, James Strauss, Manish R. Patel, Edward B. Garon, Keith D. Eaton, Tavette Neskorik, Josée Morin, Richard Chao, Balazs Halmos Category: Other Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 (see Supporting Information). Read more on pubmed
Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors
Date: 2022-02-12 Authors: Christian Kollmannsberger, Herbert Hurwitz, Lyudmila Bazhenova, Byoung Chul Cho, David Hong, Keunchil Park, Karen L. Reckamp, Sunil Sharma, Hirak Der-Torossian, James G. Christensen, Demiana Faltaos, Diane Potvin, Vanessa Tassell, Richard Chao & Geoffrey I. Shapiro Category: Other Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 […]
